The current advances of lncRNAs in breast cancer immunobiology research

Front Immunol. 2023 Jun 5:14:1194300. doi: 10.3389/fimmu.2023.1194300. eCollection 2023.

Abstract

Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related death in women worldwide. Breast cancer development and progression are mainly associated with tumor-intrinsic alterations in diverse genes and signaling pathways and with tumor-extrinsic dysregulations linked to the tumor immune microenvironment. Significantly, abnormal expression of lncRNAs affects the tumor immune microenvironment characteristics and modulates the behavior of different cancer types, including breast cancer. In this review, we provide the current advances about the role of lncRNAs as tumor-intrinsic and tumor-extrinsic modulators of the antitumoral immune response and the immune microenvironment in breast cancer, as well as lncRNAs which are potential biomarkers of tumor immune microenvironment and clinicopathological characteristics in patients, suggesting that lncRNAs are potential targets for immunotherapy in breast cancer.

Keywords: biomarker; breast cancer; immune cells; immune response; lncRNAs; prognosis; tumor immune microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / therapy
  • Female
  • Humans
  • Immunotherapy
  • RNA, Long Noncoding* / genetics
  • Research
  • Tumor Microenvironment / genetics

Substances

  • RNA, Long Noncoding

Grants and funding

This research was funded by the Consejo Nacional de Ciencia y Tecnología (CONACYT) 708515 grant (scholarship).